Point estimation for adaptive trial designs I: A methodological review

Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic tendency for the estimate of treatment effect to deviate from its true value,” and states that it is desirable to obtain and report estimates of treatment effects that reduce or remove this bias. The conventional en...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, David S., Choodari‐Oskooei, Babak, Dimairo, Munya, Flight, Laura, Pallmann, Philip, Jaki, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613995/
https://www.ncbi.nlm.nih.gov/pubmed/36451173
http://dx.doi.org/10.1002/sim.9605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613995/
https://www.ncbi.nlm.nih.gov/pubmed/36451173
http://dx.doi.org/10.1002/sim.9605

Ejemplares similares